Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P57060
UPID:
RWD2B_HUMAN
Alternative names:
-
Alternative UPACC:
P57060
Background:
The RWD domain-containing protein 2B plays a crucial role in cellular processes, with its unique RWD domain facilitating pivotal interactions within the cell. This protein, encoded by the gene symbolized as P57060, is a subject of intense study due to its potential implications in various biological pathways.
Therapeutic significance:
Understanding the role of RWD domain-containing protein 2B could open doors to potential therapeutic strategies. Its involvement in key cellular functions suggests that targeting this protein could lead to innovative treatments for diseases where these processes are disrupted.